Compare EVER & NVCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EVER | NVCT |
|---|---|---|
| Founded | 2008 | 2020 |
| Country | United States | United States |
| Employees | 356 | 13 |
| Industry | Computer Software: Programming Data Processing | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 885.7M | 608.8M |
| IPO Year | 2018 | 2021 |
| Metric | EVER | NVCT |
|---|---|---|
| Price | $25.00 | $19.20 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | ★ $27.00 | $10.00 |
| AVG Volume (30 Days) | ★ 729.3K | 525.3K |
| Earning Date | 05-04-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 198.86 | N/A |
| EPS | ★ 0.51 | N/A |
| Revenue | ★ $163,349,000.00 | N/A |
| Revenue This Year | $14.73 | N/A |
| Revenue Next Year | $11.51 | N/A |
| P/E Ratio | $48.04 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.88 | $5.55 |
| 52 Week High | $28.73 | $29.28 |
| Indicator | EVER | NVCT |
|---|---|---|
| Relative Strength Index (RSI) | 54.76 | 54.96 |
| Support Level | $23.67 | $18.02 |
| Resistance Level | $27.10 | $29.28 |
| Average True Range (ATR) | 1.43 | 1.18 |
| MACD | -0.29 | -0.31 |
| Stochastic Oscillator | 19.79 | 63.07 |
EverQuote Inc operates an online marketplace for insurance shopping, connecting consumers with insurance providers, including carriers and agents. Its marketplace is powered by proprietary data and technology platform that delivers high-intent, pre-validated consumer referrals aligned with insurers underwriting and profitability requirements. The platform provides transparency and campaign management tools, enabling providers to evaluate marketing spend performance and manage return on investment. Consumers can visit insurance provider websites, engage by phone, or submit data to receive quotes. Services are free for consumers, and the company derives revenue principally from consumer inquiries sold as referrals to insurance providers. It derives a majority of revenue from Direct channels.
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.